■ Venous thromboembolism (VTE) represents a substantial personal and economic burden.
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Effective treatment requires a balance between the prevention of recurrence and the incidence of bleeding complications. 2 Current standard of care (SOC) for acute VTE is initiation of a vitamin K antagonist (VKA)/parenteral anticoagulation, followed by ≥3 months of VKA treatment. [3] [4] [5] Recently, several studies have evaluated the use of novel oral anticoagulants (NOACs) for the initial/long-term treatment of patients with VTE, [6] [7] [8] [9] [10] [11] although no headto-head trials have currently been reported. ■ A systematic review and meta-analysis were conducted to compare the efficacy and safety of NOACs for the initial/long-term treatment of VTE.
Methods

Systematic literature review
■ A systematic review was conducted to identify studies enrolling patients receiving treatment for an acute VTE event.
─ Structured searches were conducted in MEDLINE, EMBASE, and the Cochrane Library (accessed July 2014) and supplementary hand searches were performed.
─ Studies identified in the systematic review were considered for meta-analysis if they met the inclusion criteria summarised in Table 1 .
Meta-analysis
■ A Bayesian network meta-analysis (NMA) was conducted following methodology published by the NICE Decision Support Unit.
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■ Analyses were performed on a dichotomous dataset and the treatment effect was evaluated in terms of relative risk.
■ Analyses of efficacy outcomes considered the number of events in an intention-to-treat (ITT) study population, whereas analyses of safety outcomes were based on the reported safety population.
■ A sensitivity analysis was conducted, substituting data from the individual RE-COVER 7 and RE-COVER II 8 trials with data from the pooled analysis of the RE-COVER and RE-COVER II trials. 
Results
Systematic literature review
■ From the original search, 5,021 citations were identified of which 4,966 were excluded based on the title/abstract. Fifty five papers were reviewed in full and seven publications reporting on six unique RCTs met the inclusion criteria. [6] [7] [8] [9] [10] [11] 13 The EINSTEIN pooled data 13 were used in the NMA to ensure that the source data covered a general VTE population, rather than the respective DVT and PE populations used in the individual EINSTEIN trials.
■ A summary of the baseline characteristics of the included studies is provided in Table 2 .
■ The main areas of heterogeneity between the eligible studies were:
─ Study design: The network included a mixture of open-label 6, 11 and double-blind [7] [8] [9] [10] studies ( Table 2) . While, double-blind studies may be less prone to bias than open-label studies, such a design is not always feasible in anticoagulation trials. ─ Unprovoked VTE: Unprovoked VTE varied from 63.5%-89.8% between the trials. 9, 10, 13 Patients with an unprovoked VTE may have a higher risk of recurrence 15, 16 which may result in variation in the baseline risk of VTE events between trials.
─ Definitions of primary efficacy outcomes: The 'VTE and VTE-related death' endpoint comprised reported events of DVT, fatal or non-fatal PE and VTE-related death and was reported as an adjudicated composite of recurrent VTE (including fatal or non-fatal PE and DVT) or death related to VTE; 9 composite of VTE or death associated with VTE; 7 VTE or VTE-related death; 8 or a composite of DVT and non-fatal or fatal PE. 6, 10, 11 All studies reported a consistent definition of bleeding outcomes as defined by the International Society on Thrombosis and Haemostasis.
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Network meta-analysis ■ The network of evidence for the 'VTE and VTE-related death' outcome is reported in Figure 1 . Due to the small number of studies in the network, the NMA was restricted to a fixed-effect model only.
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■ Results from the fixed-effect NMA are shown in Table 3 .
─ The results for the comparison of the individual NOACs with UFH or LMWH/warfarin confirm the findings from the individual RCTs.
─ There was no statistically significant difference in efficacy between the NOACs for 'VTE or VTE-related death' and all-cause mortality.
─ Apixaban was associated with a significantly lower risk of 'major or clinically relevant non-major (CRNM) bleeding' compared with dabigatran (↓31%), edoxaban (↓46%), or rivaroxaban (↓53%).
─ Apixaban also had a significantly lower risk of major bleeding and CRNM bleeding compared with dabigatran (↓60%) and rivaroxaban (↓53%), respectively, and for both outcomes compared with edoxaban (↓64% and ↓41% respectively).
─ Rivaroxaban was associated with a significantly higher risk of CRNM bleeding compared with dabigatran (↑70%) and edoxaban (↑26%), and 'major or CRNM bleeding' compared with dabigatran (↑48%).
─ Dabigatran treatment was associated with a significantly lower risk of 'major or CRNM bleeding' (↓23%) or CRNM bleeding (↓26%) compared with edoxaban.
─ The results of the sensitivity analysis using data from the pooled RE-COVER trials 8 support the findings observed in the primary analysis.
Inclusion criteria Description
Population
Adult patients (≥18 years of age) with an objectively confirmed VTE (DVT and/or PE), who were receiving treatment following an acute VTE event. • Recurrent VTE and VTE-related death (sum of non-fatal PE, DVT and VTE-related death outcomes)
• All-cause mortality
Safety:
• Major and/ or clinically relevant non-major (CRNM) bleeding
• Major bleeding
• CRNM bleeding The intended treatment duration (3, 6, or 12 months) was determined by the treating physician before randomisation. Abbreviations: LMWH, low molecular weight heparin; ; NR, not reported; RCT, randomised controlled trial; SD, standard deviation; UFH, unfractionated heparin; VTE, venous thromboembolism; VKA, vitamin K antagonist. Table 2 . Patient characteristics at baseline across treatment arms for the included studies ■ Apixaban demonstrated a significantly better safety profile in terms of a reduction in 'major or CRNM bleeding' compared with dabigatran, edoxaban, and rivaroxaban, which is a serious and costly complication of anticoagulation, leading to under-treatment and an increased risk of recurrent VTE.
■ The use of NOACs and apixaban in particular, may therefore reduce the burden on healthcare systems as a result of a reduced incidence of bleeding events.
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